Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of... see more

Recent & Breaking News (NDAQ:BCRX)

Where Does Merck's Ebola Vaccine Breakthrough Leave Competitors?

Benzinga.com  December 23, 2016

BioCryst to Present at the Piper Jaffray Healthcare Conference November 30

GlobeNewswire November 17, 2016

Biotech Stocks on Investors' Radar -- Inovio Pharma, Pacific Biosciences of California, BioCryst Pharma, and Sangamo Biosciences

PR Newswire November 15, 2016

Watch These 7 Huge Call Purchases In Thursday Trade

Benzinga.com  November 10, 2016

BioCryst Reports Third Quarter 2016 Financial Results

GlobeNewswire November 7, 2016

BioCryst Announces Late Breaker Presentation of Galidesivir (BCX4430) Nonclinical Results in Zika Virus Infection at IDWeek 2016

GlobeNewswire October 26, 2016

BioCryst to Announce Third Quarter 2016 Financial Results November 7

GlobeNewswire October 24, 2016

Mid-Morning Market Update: Markets Mostly Higher; Verizon Posts Mixed Q3 Results

Benzinga.com  October 20, 2016

Biotech Stocks on Investors' Radar -- Alexion Pharma, PDL BioPharma, BioCryst Pharma, and Cara Therapeutics

PR Newswire October 12, 2016

BioCryst Closes $23 Million Senior Credit Facility 

GlobeNewswire September 26, 2016

BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model

GlobeNewswire September 7, 2016

BioCryst to Present at the Baird 2016 Global Healthcare Conference September 8

GlobeNewswire August 31, 2016

Research Reports Initiation on Biotech Stocks -- Hemispherx Biopharma, Vascular Biogenics, BioCryst Pharma, and Alnylam Pharma

PR Newswire August 29, 2016

Mid-Afternoon Market Update: Guess? Jumps On Earnings Beat; Signet Jewelers Shares Tumble

Benzinga.com  August 25, 2016

BioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema

GlobeNewswire August 11, 2016

BioCryst Reports Second Quarter 2016 Financial Results

GlobeNewswire August 4, 2016

BioCryst to Announce Second Quarter 2016 Financial Results August 4

GlobeNewswire July 21, 2016

BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases

GlobeNewswire July 5, 2016

Technical Coverage of Biotechnology Stocks - Agenus, BioCryst Pharma, Cempra, and Hemispherx Biopharma

PR Newswire June 30, 2016

BioCryst to Present at Two Upcoming Investor Conferences

GlobeNewswire May 26, 2016